Find verified Prasugrel API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Prasugrel for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Prasugrel API.
Alternate Names: Prasita, Efient
CAS No: 150322-43-3
PubChem CID: 6918456
Mol Formula: C20H20FNO3S
Mol Weight: 373.4 g/mol
IUPAC Name: [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
Therapeutic use: Cardiovascular, Hematologic Agents
Drug Class: Antiplatelets, Antithrombotic agents
Commercial / Development Status: Commercial APIs
Source / Manufacturing Origin: Synthetic APIs
API Description: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
